Objective To assess the safety and efficacy of danhong injection combined with edaravone for acute cerebral infarction ( ACI) . Methods To search CBM、CNKI、VIP、WF、MEDLINE for randomized controlled trials ( RCTs) of related articles from inception to November 2014.After assessed the quality of studies included,RevMan5.2 software was used to analyze data. Results 23 studies,were included and 2 001 patients were involved.The results showed that the effective rate of danhong injection combined with edaravone for ACI was better than that of control group with statistical significance [ RR=1.23, 95%CI (1.17,1.29), P<0.000 01].Meta-analysis on the improvement of neurological deficit and activities of daily living also showed a better effectiveness of experimental group than control group with statistical significance [MD=-3.09,95%CI(-3.68,-2.50),P<0.000 01];[MD=15.15,95%CI(12.69,17.62), P<0.000 01].But the result showed no statistical significance in safety evaluation of two groups [RR=1.88,95%CI(0.76,4.63),P=0.17]. Conclusion Although the results support the conclusion that danhong injection with edaravone is safe and superior to either danhong injection or edaravone or conventional treatment, further large sample and high quality randomized controlled trials should be carried out.%目的：评价丹红注射液联合依达拉奉治疗急性脑梗死的疗效和安全性。方法通过检索中国生物医学文献数据库、中国期刊全文数据库、维普期刊数据库、万方期刊数据库、MEDLINE数据库从建库至2014年11月的中英文文献,选择符合纳入及排除标准的随机对照试验,对纳入文献进行质量评价,采用RevMan5.2版软件进行Meta分析。结果共纳入23个研究,2001例患者。丹红注射液联合依达拉奉注射液在疗效方面对比单用丹红注射液、依达拉奉注射液、丹参注射液及常规治疗有优势,疗效合并效应量[RR＝1.23,95％CI(1.17,1.29),P<0.00001]；在神经功能缺损改善方面优于丹红注射液对照组,合并效应量[ MD＝－3.09,95％CI(－3.68,－2.50),P<0.00001]；在日常生活能力改善方面比丹红注射液对照组及依达拉奉对照组有效,合并效应量[MD＝15.15,95％CI(12.69,17.62),P<0.00001]；而在安全性方面与对照组无差异,合并效应量[RR＝1.88,95％CI(0.76,4.63),P＝0.17]。结论丹红注射液联合依达拉奉注射液治疗急性脑梗死疗效较单用一种注射剂及常规治疗显著,能减轻近期致残率,且较安全,但仍需后续大样本、高质量文献关注致死率及远期致残率的研究。
展开▼
